Suzhou Zelgen Biopharmaceuticals Co., Ltd. (SHA:688266)

China flag China · Delayed Price · Currency is CNY
99.42
-0.58 (-0.58%)
Apr 28, 2026, 3:00 PM CST
-1.35%
Market Cap 26.32B
Revenue (ttm) 810.48M
Net Income (ttm) -162.95M
Shares Out 264.71M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE 47.49
Dividend n/a
Ex-Dividend Date n/a
Volume 3,093,634
Average Volume 3,305,537
Open 101.00
Previous Close 100.00
Day's Range 99.01 - 101.95
52-Week Range 75.10 - 134.17
Beta -0.00
RSI 54.71
Earnings Date Apr 29, 2026

About SHA:688266

Suzhou Zelgen Biopharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, and distribution of medicines in the People's Republic of China. The company offers donafenib tablets for hepatocellular carcinoma and iodine-refractory differentiated thyroid cancer; recombinant human thrombin for hemostasis; and jacktinib tablets for intermediate and high-risk myelofibrosis. It also develops drug candidates in the NDA, Phase III, or registration clinical trial stages, such as gecacitinib hydroch... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2009
Employees 1,055
Stock Exchange Shanghai Stock Exchange
Ticker Symbol 688266
Full Company Profile

Financial Performance

In 2025, SHA:688266's revenue was 810.48 million, an increase of 52.07% compared to the previous year's 532.95 million. Losses were -162.95 million, 18.2% more than in 2024.

Financial Statements

News

There is no news available yet.